CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
The firm reported that it expects product and service revenue of approximately $23.5 million for the fourth quarter of last year and $83.5 million for full-year 2018.
The group recommends Myriad Genetics' EndoPredict, NanoString's Prosigna, and Genomic Health's Oncotype DX tests for guiding chemotherapy decisions if certain conditions are met.
The agreement amends and restates an existing loan and security agreement between NanoString and SVB to increase the size of the revolving loan facility to $20 million.
At least two early-access users, at Massachusetts General Hospital and at Weill Cornell, have explored the new platform for infectious disease testing.
The company beat Wall Street estimates, and officials said momentum is building as the firm readies its GeoMx digital spatial profiling technology for launch.
The firms have agreed to conduct joint research using NanoString's PanCancer IO 360 panel to explore predictive signatures for MacroGenics' MGD013 clinical applications.
